AbbVie Buys Immunogen, Maker of Targeted Cancer Drugs, for $10 Billion

AbbVie announced that the company will pay $10 billion to the biotech firm Immunogen for the acquirement of an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.